Back |
home / stock / immx / immx message board
Subject | By | Source | When |
---|---|---|---|
Didnt happen, back down showing 2.20 area, reload | harry crumb | investorshub | 01/08/2023 7:44:23 PM |
Then it crashed to $1.75. | Laster | investorshub | 01/06/2023 1:51:49 PM |
$,3.07 pre on this news Immix Biopharma | subslover | investorshub | 01/06/2023 1:06:47 PM |
Stock just hit $2.40. | Laster | investorshub | 12/30/2022 5:15:10 PM |
Break $2,40 and then $2.50 and it runs | Laster | investorshub | 12/30/2022 1:54:40 PM |
word is.. very good.. | vegasandre | investorshub | 12/21/2022 7:34:20 PM |
Shorts will take this down to the 1.20s, | harry crumb | investorshub | 12/15/2022 12:41:08 PM |
znewcar1: $IMMX 23% v59,6M C1.80 f13,9M H2.52 ML87 LL.68 | znewcar1 | investorshangout | 12/15/2022 12:59:08 AM |
so float is under 6 mill . outstanding | vegasandre | investorshub | 12/14/2022 4:36:11 PM |
super low float... | vegasandre | investorshub | 12/14/2022 3:33:35 PM |
I agree...it never holds. I lost big-time on | Pedro2004 | investorshub | 12/14/2022 2:45:03 PM |
It wont hold. Never does. Timberrrrr | Jess070283 | investorshub | 12/14/2022 2:35:23 PM |
Immix Biopharma in-licenses NXC-201, BCMA-targeted Next-Generation CAR-T Therapy | subslover | investorshub | 12/14/2022 2:19:27 PM |
ImmixBio Releases and Ships Scaled-Up GMP Batches of | subslover | investorshub | 12/12/2022 2:38:19 PM |
znewcar1: IMMX 29% v42,4M c2.39 f13,8M H2.7599 gapNtrap rip to HOD then slide under of YL1.77 20dma@ | znewcar1 | investorshangout | 06/02/2022 10:55:36 PM |
znewcar1: IMMX 30% v111M c2.12 f13,8M H2.87 mostly sideways since gap up Bear trap on the 2nd BO>2.8 | znewcar1 | investorshangout | 05/20/2022 11:11:38 PM |
znewcar1: IMMX 25% v1,7M c1.63 f13,8M H1.6881 ML1.25 | znewcar1 | investorshangout | 05/20/2022 2:47:26 AM |
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...